Oryx Biotech, a subsidiary of Oryx Biotech Holdings based in China, inked a tripartite agreement with Summit Technopolis and Bangladesh High Tech Park Authority (BHTPA) for a biotech investment worth USD 300 Million.
Oryx will set up their Plasma Fractionation Plant in Block II of Summit Technopolis to produce plasma derivatives also known as Life Saving Therapeutics and other related products - making it the first biotech investment in Bangladesh.
With a great need for plasma in the potential treatment of COVID-19, this is a timely investment for Bangladesh’s healthcare research and service sectors. It is expected that about 2,000 high-value science graduates will be employed to produce therapeutics such as Albumin, Immunoglobulin, Coagulation factor VIII, etc.
The deal signing was witnessed by State Minister for Power, Energy and Mineral Resources Nasrul Hamid, ICT State Minister Zunaid Ahmed Palak, Senior Secretary of ICT Division N M Zeaul Alam, Managing Director of BHTPA Hosne Ara Begum.
State Minister for Power, Energy and Mineral Resources Nasrul Hamid said, “The role played by the ICT department in tackling Corona has been lauded across the country.
The ICT department has worked tirelessly to ensure the best use of technology to prevent coronary infections. The countrymen have benefited from many initiatives like Live Corona Test, Covid-19 Tracker, Tele-Medicine and Telehealth, Comrade-Plasma Platform etc. From this, the picture of progress of ICT sector of a country is clear”.
ICT State Minister Zunaid Ahmed Palak said, “At present, 37 companies have been allotted land in 'Bangabandhu Hi-Tech City' which is set up on 355 acres of land.
Already five companies have started production there. The companies will work in the park with high technology such as mobile phone assembling and manufacturing, optical cable, hardware, software, data-center etc.
Till now Tk 328 crore has already been invested and about 13,000 people have been employed. We are hopeful that Tk 2,400 crore will be invested in high-tech parks by 2025”.
Muhammed Aziz Khan, Founder Chairman of Summit said, “We are pleased to activate the nation's first and largest biotech investment of about USD 300 million on 25 acres of land and building provided by Summit Technopolis.
It is most gratifying that this milestone plasma fractionation project which will open new horizons in Bangladesh’s development is happening in this auspicious year of Bangabandhu’s birth centenary.”
The ceremony was virtually attended by Muhammed Aziz Khan, Vice-Chairmen of Summit Group Jafer Ummeed Khan, Latif Khan, Farid Khan, Directors of Summit Group Ayesha Aziz Khan, Azeeza Aziz Khan, Fadiah Khan, Salman Khan along with other senior officials and David Bo and his colleagues from China.